Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.
about
The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidolThe antipsychotic potential of muscarinic allosteric modulationNovel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.A genome-wide investigation of SNPs and CNVs in schizophrenia.Fortnightly review. Treatment of schizophrenia.Conventional versus novel antipsychotics: changing concepts and clinical implicationsSwitching antipsychotic therapies.Measuring neuropsychological change in schizophrenia with novel antipsychotic medicationsTreating cognitive dysfunction in patients with schizophreniaCognitive neurosciences: A new paradigm in management and outcome of schizophreniaCognition in schizophrenia: Past, present, and future.Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical studyCognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders.Cognition, schizophrenia, and the atypical antipsychotic drugsThe Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement.Symptom domains of schizophrenia: the role of atypical antipsychotic agents.Towards a muscarinic hypothesis of schizophrenia.Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase.Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.Clozapine use in a forensic population in a New South Wales prison hospital.In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.A systematic review of the evidence of clozapine's anti-aggressive effects.Insight in schizophrenia: from conceptualization to neuroscience.Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.Neurocognitive impairment in schizophrenia and how it affects treatment options.Impact of Pharmacist Counselling on Clozapine Knowledge.Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.Schizophrenia and antipsychotic somatic treatment.Cognitive models in a fuller understanding of schizophrenia.Did I say that word or did you? Executive dysfunctions in schizophrenic patients affect memory efficiency, but not source attributions.Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence.
P2860
Q25256710-1D2DEECA-DF55-452C-AB6A-88A12D8FCFDCQ28362116-31B66CD9-ABCC-4E81-B73A-24569A8840ABQ28603221-1A18C334-FBF5-4A98-B49B-9B05593E3C24Q30501297-111278B3-5193-407C-8C09-C7838085C59BQ30524240-F53472ED-F69D-4B49-8441-568B2A65899AQ33238062-280E936D-E44C-4217-B974-B3E6DE87CE42Q33406258-12565A70-92D9-4F3C-BCC5-0BA9C86F525DQ33751787-D4468F84-D2DF-4CAF-AEE4-FECA05430139Q33787546-78764CCE-644A-4A33-87C1-9ABC900098EBQ33838916-894B65F6-2C1E-40C7-98E3-73291E1EDFE4Q33877837-73B98DEF-5F5C-4545-9404-8D5DC1B39024Q33877844-FE9C136A-B25E-4BFE-925C-C0DD99D65AA3Q34082617-2B3A1BD6-01A5-49E2-B363-422CA32F54ADQ34224025-83501E7A-1859-4023-83E7-AEB7C7930563Q34249753-69692541-B45B-4F76-99A7-BB5C63CBB3BFQ34419652-813409F6-D67C-4734-902F-9F3B3D312B1EQ34665354-F79BBF45-C640-40B7-9134-8B5A4A6DF6CCQ35618437-2AF1F83C-E49F-4CA6-9AE0-59622A0FC5D1Q36086075-4D23629B-F8AD-4547-A6D2-BD3A547531A8Q36224865-069727FF-A6B3-4799-9376-C125404DE1AEQ36626242-AD61710F-7B59-4556-8188-20FC3F2B794BQ36673957-7479F1AE-98A6-4041-90DC-94827D340D0EQ36715888-B20389A4-E8BF-4D08-BC31-3A04809F9A6DQ36907446-1CEA425E-81CF-4CC4-A313-1D9C42A17E28Q36917265-00D8CD25-EFEF-4ED7-A360-E6364CDF7660Q37057976-C486EBFD-FEE5-4FC2-AF1F-9B9199F2E211Q37870701-08E31818-7409-4328-A2A9-CB4885A8C704Q37983747-E96CA34A-78CD-47DC-9346-7C374A882A7DQ37984684-623C9ECE-CEC2-4FA3-B84F-EF617BA0673DQ37996450-8FC0DD3B-6147-4138-BFA6-E696E62ED1DEQ38149953-6AC8B957-7863-4F94-99AF-BEADC9327F8DQ38624047-11C9CA74-1BE8-48D6-B36E-3002D8E42CB0Q39172080-63DDE43F-55B0-42B4-BB20-60675A0FCEE3Q40899543-942DA823-493B-465B-9486-1B4B223BBC6AQ41037996-E2E7A85D-A28A-4E37-ADE4-CAB0045C1896Q41194504-E042726C-287F-4237-925E-7582BACED3C0Q41459295-BED0E694-A40F-41AB-9441-506781618584Q41699193-C8473EB8-BD95-47A5-A7B4-65263A22CF70Q43782519-55EDFCC2-69FD-45C7-BEFF-619D7C68C124Q44386854-0B296B1D-FE54-4AEC-8C35-A56839320A2C
P2860
Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Improvement in cognitive funct ...... patients receiving clozapine.
@en
Improvement in cognitive funct ...... patients receiving clozapine.
@nl
type
label
Improvement in cognitive funct ...... patients receiving clozapine.
@en
Improvement in cognitive funct ...... patients receiving clozapine.
@nl
prefLabel
Improvement in cognitive funct ...... patients receiving clozapine.
@en
Improvement in cognitive funct ...... patients receiving clozapine.
@nl
P2093
P1476
Improvement in cognitive funct ...... patients receiving clozapine.
@en
P2093
P304
P356
10.1016/0006-3223(93)90043-D
P407
P577
1993-11-01T00:00:00Z